NDC 63187-574 – Acyclovir
Acyclovir 800 mg/1 · Tablet · Oral
Product NDC63187-574
Product details
- Brand name
- Acyclovir
- Generic name
- Acyclovir
- Labeler
- Proficient Rx LP
- Dosage form
- Tablet
- Route
- Oral
- Marketing category
- ANDA · ANDA203834
- Marketed since
- November 29, 2013
- Listing expires
- December 31, 2026
- Pharmacologic class
- Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Active ingredients
- Acyclovir 800 mg/1
Package NDC codes (8)
| Package NDC | Description | Since |
|---|---|---|
| 63187-574-06 | 6 TABLET in 1 BOTTLE (63187-574-06) | Sep 4, 2018 |
| 63187-574-20 | 20 TABLET in 1 BOTTLE (63187-574-20) | Feb 2, 2015 |
| 63187-574-25 | 25 TABLET in 1 BOTTLE (63187-574-25) | Feb 1, 2019 |
| 63187-574-30 | 30 TABLET in 1 BOTTLE (63187-574-30) | Feb 2, 2015 |
| 63187-574-35 | 35 TABLET in 1 BOTTLE (63187-574-35) | Feb 2, 2015 |
| 63187-574-50 | 50 TABLET in 1 BOTTLE (63187-574-50) | Feb 2, 2015 |
| 63187-574-60 | 60 TABLET in 1 BOTTLE (63187-574-60) | Feb 2, 2015 |
| 63187-574-90 | 90 TABLET in 1 BOTTLE (63187-574-90) | Feb 2, 2015 |
Other Acyclovir products
- 50090-3254 Acyclovir 400 mg/1 · Tablet · A-S Medication Solutions
- 50090-7276 Acyclovir 400 mg/1 · Tablet · A-S Medication Solutions
- 50090-6844 Acyclovir 400 mg/1 · Tablet · A-S Medication Solutions
- 50090-6578 Acyclovir 800 mg/1 · Tablet · A-S Medication Solutions
- 50090-7277 Acyclovir 400 mg/1 · Tablet · A-S Medication Solutions
- 50090-3250 Acyclovir 400 mg/1 · Tablet · A-S Medication Solutions
- 50090-6335 Acyclovir 800 mg/1 · Tablet · A-S Medication Solutions
- 50090-7275 Acyclovir 400 mg/1 · Tablet · A-S Medication Solutions
- 80425-0270 Acyclovir 400 mg/1 · Tablet · Advanced Rx Pharmacy of Tennessee, LLC
- 60687-856 Acyclovir 400 mg/1 · Tablet · American Health Packaging
- 60687-867 Acyclovir 800 mg/1 · Tablet · American Health Packaging
- 60505-5306 Acyclovir 400 mg/1 · Tablet · Apotex Corp.